scroll to top
Press enter or spacebar to select a desired language.
Press enter or spacebar to select a desired language.
Your source for trusted research content

EBSCO Auth Banner

Let's find your institution. Click here.

Exogenous modulation of intrinsic optic nerve neuroprotective activity.

  • Academic Journal
  • Grozdanic SD; Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
    Lazic T
    Kuehn MH
    Harper MM
    Kardon RH
    Kwon YH
    Lavik EB
    Sakaguchi DS
  • Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie [Graefes Arch Clin Exp Ophthalmol] 2010 Aug; Vol. 248 (8), pp. 1105-16. Date of Electronic Publication: 2010 Mar 13.
  • English
  • Background: To characterize the molecular and functional status of the rat retina and optic nerve after acute elevation of intraocular pressure (IOP).
    Methods: Retinal ischemia was induced in rats by increasing the IOP (110 mmHg/60 minutes). Microarray analysis, quantitative RT-PCR (qRT-PCR) and immunohistochemistry were used to characterize retinal tissue. PLGA microspheres containing neurotrophic factors (BDNF, GDNF, or CNTF) or empty microspheres were injected into the vitreous of operated animals 1 day after elevation of IOP. Pupil light reflex (PLR) parameters and electroretinograms (ERG) were monitored at multiple time points during the 60-day postoperative recovery period.
    Results: Molecular analysis showed a significant intrinsic up-regulation of CNTF at 10 and 25 days after induction of the acute ocular hypertension (p = 0.0067). Molecular tissue analysis of GDNF and its receptors (GDNFR1, GDNFR2), and BDNF and its receptor (trkB) showed no change in expression. Animals that received CNTF microspheres had no significant functional recovery compared to animals which received blank microspheres (p > 0.05). Animals that received GDNF or BDNF microspheres showed significant PLR recovery (p < 0.05 and p < 0.001 respectively) compared to non-treated animals.
    Conclusions: Continuous release of neurotrophic growth factors (NGFs) significantly protects optic nerve function in the experimental model of retinal ischemia observed by PLR analysis.
Additional Information
Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 8205248 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1435-702X (Electronic) Linking ISSN: 0721832X NLM ISO Abbreviation: Graefes Arch Clin Exp Ophthalmol Subsets: MEDLINE
Original Publication: Berlin ; New York : Springer-Verlag, c1982-
Exp Eye Res. 1998 Jun;66(6):791-805. (PMID: 9657912)
Invest Ophthalmol Vis Sci. 1998 Mar;39(3):592-602. (PMID: 9501871)
Neuroreport. 1999 Feb 5;10(2):419-22. (PMID: 10203346)
Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2724-34. (PMID: 10509671)
Expert Opin Biol Ther. 2005 Nov;5(11):1443-52. (PMID: 16255648)
Exp Eye Res. 2006 Apr;82(4):597-607. (PMID: 16213484)
Exp Eye Res. 2006 Mar;82(3):395-404. (PMID: 16143329)
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2512-7. (PMID: 16473951)
Am J Ophthalmol. 2006 Jul;142(1):88-94. (PMID: 16815255)
J Pharm Sci. 2007 Mar;96(3):558-68. (PMID: 17177208)
Exp Eye Res. 2007 Apr;84(4):753-71. (PMID: 17320077)
Biotechnol Bioeng. 2008 Aug 1;100(5):1010-9. (PMID: 18431801)
Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11249-53. (PMID: 1454803)
Neuron. 2000 May;26(2):533-41. (PMID: 10839371)
Brain Res. 2000 Jun 23;868(2):358-62. (PMID: 10854589)
Invest Ophthalmol Vis Sci. 2000 Sep;41(10):2967-71. (PMID: 10967052)
Neuroreport. 2000 Nov 27;11(17):3893-6. (PMID: 11117510)
J Biomed Mater Res. 2001 May 1;58(3):291-4. (PMID: 11319743)
Neurosci Lett. 2001 Jun 8;305(2):139-42. (PMID: 11376903)
J Neurosci. 2002 Nov 1;22(21):9228-36. (PMID: 12417648)
Curr Eye Res. 2002 Aug;25(2):69-78. (PMID: 12525960)
Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2597-605. (PMID: 12766062)
Exp Eye Res. 2003 Jul;77(1):27-33. (PMID: 12823985)
J Pharm Sci. 2003 Aug;92(8):1582-91. (PMID: 12884245)
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4337-46. (PMID: 14507878)
Invest Ophthalmol Vis Sci. 2003 Oct;44(10):4357-65. (PMID: 14507880)
Neuroscience. 2003;122(1):229-35. (PMID: 14596863)
Eur J Neurosci. 2004 Jan;19(2):265-72. (PMID: 14725620)
Exp Eye Res. 2004 Jul;79(1):75-83. (PMID: 15183102)
Brain Res. 2004 Jul 9;1013(2):152-8. (PMID: 15193523)
Exp Eye Res. 2004 Oct;79(4):513-24. (PMID: 15381035)
Exp Eye Res. 1991 Nov;53(5):573-82. (PMID: 1743256)
J Neurosci. 1995 Nov;15(11):7377-85. (PMID: 7472491)
Graefes Arch Clin Exp Ophthalmol. 1996 Jul;234(7):445-51. (PMID: 8817288)
Exp Eye Res. 1997 Aug;65(2):241-8. (PMID: 9268592)
J Neurosci. 1998 Feb 15;18(4):1337-44. (PMID: 9454843)
Prog Retin Eye Res. 1999 Jan;18(1):39-57. (PMID: 9920498)
R01 EY019485 United States EY NEI NIH HHS; R01 NS044007 United States NS NINDS NIH HHS; EY019294 United States EY NEI NIH HHS; NS044007 United States NS NINDS NIH HHS; EY019485 United States EY NEI NIH HHS; R01 EY019294 United States EY NEI NIH HHS
0 (Brain-Derived Neurotrophic Factor)
0 (Ciliary Neurotrophic Factor)
0 (Glial Cell Line-Derived Neurotrophic Factor)
0 (Glial Cell Line-Derived Neurotrophic Factor Receptors)
0 (Nerve Growth Factors)
0 (Neuroprotective Agents)
1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
26009-03-0 (Polyglycolic Acid)
33X04XA5AT (Lactic Acid)
EC (Receptor, trkB)
Date Created: 20100316 Date Completed: 20100830 Latest Revision: 20181201